`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`MEDTRONIC, INC., AND MEDTRONIC VASCULAR, INC.
`Petitioners,
`
`v.
`
`TELEFLEX INNOVATIONS S.A.R.L.
`Patent Owner.
`
`
`
`
`Case IPR2020-01341
`Case IPR2020-01342
`Patent 8,142,413
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`DECLARATION OF PETER T. KEITH
`IN SUPPORT OF MOTIONS TO AMEND
`U.S. PATENT 8,142,413
`
`
`
`
`
`
`
`
`
`TABLE OF CONTENTS
`
`PERSONAL BACKGROUND ....................................................................... 1
`I.
`II. MATERIALS CONSIDERED ........................................................................ 4
`III. LEGAL STANDARDS ................................................................................... 5
`A. Claim Construction................................................................................ 5
`B. Written Description ............................................................................... 5
`IV. SCOPE OF OPINIONS ................................................................................... 6
`V. PERSON OF ORDINARY SKILL IN THE ART .......................................... 6
`VI. THE TELEFLEX PATENTS .......................................................................... 7
`VII. WRITTEN DESCRIPTION ..........................................................................11
`A. Substitute Claim 15 .............................................................................11
`B.
`Substitute Claim 16 .............................................................................16
`C.
`Substitute Claim 17 .............................................................................18
`VIII. NEXUS ..........................................................................................................18
`
`
`
`
`
`
`i
`
`
`
`I, Peter Keith, hereby declare and state as follows:
`
`
`
`I have been retained by the owner of U.S. Patent No. 8,142,413 (“the
`
`’413 patent”), whom I will refer to in this declaration as “Teleflex,” to provide my
`
`independent expert opinions in this matter. I understand that a petition for inter
`
`partes review (“IPR”) has been filed against certain claims of the ’413 and other
`
`Teleflex patents, which I refer to as the “GuideLiner patents.” I submit this
`
`declaration in support of Teleflex’s Motion to Amend U.S. Patent No. 8,142,413.
`
`I.
`
`PERSONAL BACKGROUND
`I summarize my educational background and career history in the
`
`
`following paragraphs. My complete qualifications are provided in my curriculum
`
`vitae, which is attached to this declaration as Appendix A.
`
`
`
`I received a Bachelor of Science degree in mechanical engineering
`
`with High Distinction from the University of Minnesota in 1987. During my
`
`undergraduate training, I began working as an engineering intern in the research
`
`and development (R&D) department at SCIMED, which was later acquired by
`
`Boston Scientific Corporation. I joined SCIMED full-time after graduation, and I
`
`remained with the company until 1996. During this time I rose from engineering
`
`intern to full-time R&D engineer to Director of R&D. Throughout my various
`
`roles at SCIMED, the focus of my work was on medical devices in the field of
`
`interventional cardiology, particularly catheter design.
`
`1
`
`
`
`
`
`Since 1997, I have served as an independent consultant for early stage
`
`medical device companies in the areas of product design and intellectual property
`
`development. Many of my consulting clients and/or the products they developed
`
`with my assistance were subsequently acquired by large medical technology
`
`companies, including St. Jude Medical/Abbott, Johnson & Johnson, Teleflex,
`
`Edwards Lifesciences and LivaNova. A number of the products that I have
`
`consulted on have been in the field of interventional cardiology, particularly
`
`catheters.
`
`
`
`In addition to my work as an independent consultant, since 2000 I
`
`have engaged in a number of entrepreneurial ventures in the field of medical
`
`devices. In many of these ventures, I held chief responsibility for product design
`
`and development. Several of these products have been in the area of interventional
`
`cardiology. I have also done considerable work outside the area of interventional
`
`cardiology, including in treatments for orthopedics for extremities such as feet and
`
`ankles and treatment of spinal disorders. In 2006, I co-founded Entellus Medical, a
`
`company focused on catheter-based treatments for chronic sinusitis. As Chief
`
`Technology Officer, I led the product development and research teams. Entellus
`
`successfully commercialized a series of ground-breaking products developed under
`
`my leadership. Entellus went public in 2015, and was acquired by Stryker in 2018
`
`for over $600 million.
`
`2
`
`
`
`
`
`Between my work at SCIMED, my independent consulting, and my
`
`entrepreneurial ventures, I have been named as an inventor on over 140 issued U.S.
`
`patents, as well as many corresponding patents in foreign countries. Numerous
`
`additional patent applications on which I am a named inventor are still pending.
`
`Many of these patents concern catheters.
`
`
`
`I have prior experience with patent litigation involving the technology
`
`at issue and the GuideLiner patents. Among other things, I provided expert
`
`analysis on behalf of Teleflex in the case of QXMédical, LLC v. Vascular Solutions
`
`LLC, et al., No. 0:17-cv-01969 (D. Minn.) (the QXM case). In the QXM case,
`
`among the patents asserted were four of the five GuideLiner patents at issue in
`
`these IPRs: U.S. Patent Nos. 8,048,032; RE45,380; RE45,760; and RE45,776.
`
`U.S. Patent No. RE47,379 had not yet issued when the QXM case was filed, but it
`
`is in the same family as the other four patents listed above that were asserted in the
`
`QXM case.
`
`
`
`I also provided expert opinions concerning the GuideLiner patents at
`
`issue in these IPRs on behalf of Teleflex in the case of Vascular Solutions LLC, et
`
`al. v. Medtronic, Inc., et al., No. 19-cv-01760 (D. Minn.), in connection with
`
`Teleflex’s Motion for Preliminary Injunction.
`
`3
`
`
`
`
`
`I am being compensated at $525 per hour for my time, my standard
`
`rate for this type of consulting activity. My compensation is not contingent on the
`
`results of these or any other legal proceedings.
`
`II. MATERIALS CONSIDERED
`In writing this declaration, I have considered my own knowledge and
`
`
`experience, including my work experience in designing medical devices including
`
`catheters and my experience in working with others involved in the field of
`
`interventional cardiology devices, including medical doctors working as
`
`interventional cardiologists. I have also considered the information that a person
`
`of ordinary skill in the art (“POSITA”) would have been aware of as of the date of
`
`invention of the GuideLiner patents, including the documents I discuss in this
`
`declaration.
`
`
`
`
`
`I have also reviewed the ’413 patent and its file history.
`
`I reviewed the Petitions filed in the IPR2020-01341 and IPR2020-
`
`01342 matters, the declarations of Dr. Brecker and Dr. Hillstead that accompanied
`
`these Petitions, and the documents cited in the declarations. I also have reviewed
`
`the Institution Decisions issued by the Patent Trial and Appeal Board for IPR2020-
`
`01341 and IPR2020-01342.
`
`
`
`I have also reviewed the additional documents and materials I cite or
`
`discuss in this declaration.
`
`4
`
`
`
`III. LEGAL STANDARDS
`I am not an attorney and I have not independently researched the law
`
`
`on patentability. I have been informed by counsel of the legal standards below.
`
` Claim Construction
`I understand that patent claims are to be interpreted in view of a
`
`
`patent’s specification and prosecution history. I understand that claim construction
`
`starts with the plain language of the claims as understood by a person having
`
`ordinary skill in the art at the time the patent was filed. I understand that a
`
`patentee may be his/her own lexicographer, so long as the definition of a specific
`
`term is clearly set forth in the specification and it is clear the inventor intended to
`
`define the term.
`
`B. Written Description
`I have been informed that a patent’s specification must contain an
`
`
`adequate written description of the claimed invention. I have been informed that
`
`the standard for assessing the adequacy of the written description is whether the
`
`description reasonably would convey to a POSITA that the inventor(s) had
`
`possession of the claimed subject matter by the filing date of the original
`
`application. I have been informed that the written description requirement may be
`
`satisfied by any combination of the words, structures, figures, diagrams, formulas,
`
`etc., contained in a patent, and that drawings, in particular, constitute an adequate
`
`5
`
`
`
`description if they describe, and convey to those of skill in the art that the patentee
`
`invented, what is claimed.
`
`IV. SCOPE OF OPINIONS
`I have been asked only to provide my independent opinions and
`
`
`analysis of the issues I specifically discuss in this declaration. I note that the
`
`Petitions (and the evidence they cite) appear to raise many other issues, but I have
`
`not been asked to provide my opinions as to any of those other issues for this
`
`declaration.
`
`
`
`I am not aware of any prior art that is closer to the substitute claims in
`
`Teleflex’s motions to amend than that raised in the present IPR proceedings. No
`
`prior art known to me, including that cited by Petitioner in these IPR proceedings,
`
`describes what is recited in the substitute claims presented in the motion to amend
`
`the ’413 patent. It is my opinion that the substitute claims in Teleflex’s motions to
`
`amend are patentable over the prior art of which I am aware.
`
`V.
`
`PERSON OF ORDINARY SKILL IN THE ART
`I provide my opinions with respect to the definition of a POSITA
`
`
`offered by Petitioner, e.g., IPR2020-01341 Petition, 11-12, which I meet.
`
`
`
`I understand that when considering the validity of the claims
`
`challenged by the Petitioner, I am to analyze the patents, the prior art, and any
`
`other references from the perspective of a POSITA at the time of invention. I
`
`6
`
`
`
`understand that this date is no later than May 3, 2006, the date on which the
`
`earliest patent application for the family of GuideLiner patents was filed.
`
`Therefore, when I provide my opinions, I note that they are from the perspective of
`
`a POSITA in May 2006. My opinions would be the same if the relevant date of
`
`invention is sometime in 2005, rather than May 2006.
`
`VI. THE TELEFLEX PATENTS
` The Teleflex patents describe the invention of a “coaxial guide
`
`catheter” that is designed for use with interventional cardiology devices. IPR2020-
`
`001341, Ex-1003, 49.1 The coaxial guide catheter, which is also known as a guide
`
`extension catheter and is embodied by the GuideLiner products, increases the
`
`backup support for catheters that are inserted into the coronary arteries from the
`
`aorta. Id., 3:10-12. As described in the disclosure, the guide extension catheter of
`
`the invention generally includes, from distal to proximal direction, a soft tip
`
`portion, a tubular portion, and a substantially rigid portion that has a rail segment
`
`to permit delivery without blocking use of the guide catheter. E.g., id., 32:4-5,
`
`Figs. 1, 4, 20-22. One advantage this design has is that it only minimally reduces
`
`
`11 All citations in this declaration to the application for the ’413 patent are to
`
`IPR2020-01341, Ex-1003. These citations are in the form, e.g., “Ex-1003, XX,”
`
`where XX is the page of Exhibit 1003 rather than the page of the application.
`
`7
`
`
`
`the available space inside the lumen of the guide extension to deliver interventional
`
`cardiology devices—by no more than one French size smaller than the guide
`
`catheter in the preferred embodiment. Id., 25:8-18.
`
` The guide extension catheter has structure designed to facilitate the
`
`insertion of interventional cardiology devices, including stent and balloon
`
`catheters, into its proximal end while the guide extension catheter is inside a
`
`standard guide catheter. The specification explains that the guide extension
`
`catheter preferably has a full circumference portion (34, blue), a hemicylindrical
`
`portion (36, green), and an arcuate portion (38, purple):
`
`
`
`Id., 33:6-14, Fig. 4 (color added). Inclined portions can be seen on either side of
`
`the non-inclined hemicylindrical portion 36.
`
` The guide extension catheter is designed to be used with a
`
`conventional guide catheter. Id., 39:19-40:10. First, the guide catheter is inserted
`
`through the vasculature and seated in the ostium of a smaller branch vessel. Id.,
`
`39:19-40:1. Then the guide extension catheter (along with an optional protective
`
`“inner catheter” that functions to protect the vasculature from the distal end of the
`
`guide extension catheter) is inserted into the guide catheter. Id., 40:1-7. The
`
`combination of the guide extension catheter and the protective inner catheter is
`
`8
`
`
`
`inserted through the guide catheter until the distal end of the guide extension
`
`catheter emerges from the distal end of the guide catheter and travels deeper into
`
`the branch vessel. Id. Then, the protective inner catheter is withdrawn. Id., 40:7-
`
`8. Finally, an interventional cardiology device such as a stent or balloon catheter is
`
`inserted into the lumen of the guide catheter, travels down the guide catheter and
`
`then into the lumen of the coaxial guide extension catheter, and finally out the
`
`distal end of the guide extension catheter to a desired location of treatment. Id.,
`
`40:7-18.
`
` One of the important benefits of the invention is increased “backup
`
`support.” This is important to countering the guide catheter back-out problem with
`
`complex coronary stenosis. As the patents teach, when treating a stenosis, a guide
`
`catheter is typically guided into the ostium (opening) of the branch artery to be
`
`treated, and a guidewire is passed through the lumen of the guide catheter and
`
`advanced into the artery beyond the stenosis. Id., 21:16-22:2.
`
`
`
`I have reproduced Figure 7 from the disclosure below, adding color to
`
`show a typical guide catheter 56 (pink) inserted into the ostium 60 of a coronary
`
`artery, with a guidewire 64 passing through the guide catheter and attempting to
`
`cross a stenotic lesion 66:
`
`9
`
`
`
`
`
`Id., 34:20-35:8. When the wire or an interventional cardiology device such as a
`
`stent or balloon catheter runs into a difficult or complex lesion, pushing it within or
`
`across the lesion can create backward force strong enough to dislodge the guide
`
`catheter’s distal end from the ostium. Id., 22:2-3, 28:14-19. The phantom guide
`
`catheter (yellow) in Figure 7 shows how backward force generated by the
`
`advancing device can cause the guide catheter to dislodge or back out from the
`
`ostium.
`
` The guide extension catheter, inserted beyond the end of the guide
`
`catheter deeper into the branch vessel, provides increased backup support for the
`
`guide catheter inserted into a coronary artery and prevents this problem. Id., 21:2-
`
`4. In Figure 9 from the patents, I illustrate how the guide extension catheter 12
`
`10
`
`
`
`(orange with blue tip) is inserted past the distal end of the guide catheter and deep
`
`into the coronary artery:
`
`
`
`VII. WRITTEN DESCRIPTION
`I have been asked to provide my opinions as to whether the Teleflex
`
`
`patents provide adequate written description for elements claimed in the patents.
`
`
`
`It is my opinion that the priority application discloses all elements of
`
`all claims, as set forth below.
`
`A.
`
`
`
`Substitute Claim 15
`I understand that substitute claim 15 reads as follows:
`
`Substitute claim 15 (replaces claim 1). A method of providing backup
`
`support for a treatment catheter that includes a stent an interventional cardiology
`
`device for use in the coronary vasculature, the treatment catheter that includes a
`
`11
`
`
`
`stent interventional cardiology device being adapted to be passed through a
`
`standard guide catheter, the standard guide catheter having a continuous lumen
`
`extending for a predefined length from a proximal end at a hemostatic valve to a
`
`distal end adapted to be placed in an ostium of a branch artery that branches off
`
`from a first artery, the continuous lumen of the standard guide catheter having a
`
`circular cross-sectional inner diameter sized such that the treatment catheter that
`
`includes a stent is interventional cardiology devices are insertable into and through
`
`the continuous lumen, the method comprising the following steps in the order
`
`recited:
`
`inserting the standard guide catheter into [[a]] the first artery over a
`
`guidewire, the standard guide catheter having a distal end;
`
`positioning the distal end of the standard guide catheter in [[a]] the ostium of
`
`the branch artery that branches off from the first artery;
`
`inserting a cylindrical flexible tip portion of a coaxial guide catheter, the
`
`flexible tip portion defining a tubular structure having a circular cross-section with
`
`a single lumen that is coaxial with the lumen of the standard guide catheter, an
`
`inner diameter not more than about one French smaller than the inner diameter of
`
`the standard guide catheter, a cross-sectional outer diameter, and a length that is
`
`shorter than the predefined length of the continuous lumen of the standard guide
`
`catheter, into the continuous lumen of the standard guide catheter, and,
`
`12
`
`
`
`further inserting a substantially rigid portion of the coaxial guide catheter
`
`that is proximal of, operably connected to, and more rigid along a longitudinal axis
`
`than the flexible tip portion, into the continuous lumen of the standard guide
`
`catheter, the substantially rigid portion defining a rail structure without a lumen
`
`and having a maximal cross-sectional dimension at a proximal portion that is
`
`smaller than the cross-sectional outer diameter of the flexible tip portion and
`
`having a length that, when combined with the length of the flexible distal tip
`
`portion, defines a total length of the coaxial guide catheter device along the
`
`longitudinal axis that is longer than the length of the continuous lumen of the
`
`standard guide catheter, wherein a distal portion of the substantially rigid portion
`
`includes a side opening that is sized and configured to receive the treatment
`
`catheter that includes a stent;
`
`advancing a distal portion of the flexible tip portion distally beyond the
`
`distal end of the standard guide catheter and into the branch second artery such that
`
`the distal portion of the flexible tip portion extends into the branch second artery
`
`and such that at least a portion of the proximal portion of the substantially rigid
`
`portion extends proximally through the hemostatic valve; and
`
`inserting the interventional cardiology device treatment catheter that
`
`includes a stent into and through the continuous lumen of the standard guide
`
`catheter alongside the rail structure of the substantially rigid portion and advancing
`
`13
`
`
`
`the interventional cardiology device treatment catheter that includes a stent through
`
`the side opening and beyond [[a]] the single lumen of the flexible tip portion into
`
`contact with or past a lesion in the branch second artery.
`
`
`
`It is my opinion that all elements of substitute claim 15 are supported
`
`by the application. Specifically, the priority application discloses a method of
`
`providing backup support for a treatment catheter that includes a stent for use in
`
`the coronary vasculature and is adapted to be passed through a standard guide
`
`catheter. Ex-1003, 25:5-7; 28:1-29:12; 30:13-20; 34:20-36:10; 39:19-40:18; 55-
`
`57.
`
` The priority application further discloses that the standard guide
`
`catheter has a continuous lumen that extends for a predefined length from a
`
`proximal end at a hemostatic valve to a distal end adapted to be placed in an
`
`ostium of a branch artery that branches off from a first artery, where the continuous
`
`lumen of the standard guide catheter has a circular cross-sectional inner diameter
`
`sized such that the treatment catheter that includes a stent is insertable into and
`
`through the continuous lumen. Id., 21:26-22:2; 25:3-18; 28:1-19; 29:15-16; 30:13-
`
`15; 34:20-35:12; 55.
`
` The application discloses that the method includes a series of
`
`sequential steps that includes inserting the standard guide catheter into the first
`
`artery over a guidewire, positioning the distal end of the standard guide catheter in
`
`14
`
`
`
`the ostium of the branch artery, id., 21:25-22:2; 27:17-28:6; 28:14-19; 30:13-15;
`
`34:20-35:8; 39:19-40:10; 55, and then inserting a cylindrical flexible tip portion of
`
`a coaxial guide catheter into the continuous lumen of the standard guide catheter,
`
`id., 24:14-16; 26:3-16; 27:17-28:6; 30:1-2, 5-6, 9-10, 16-18; 32:4-20; 35:13-20;
`
`40:1-8; 50; 52; 54; 56, where the flexible tip portion defines a tubular structure
`
`having a circular cross-section with a single lumen that is coaxial with the lumen
`
`of the standard guide catheter and has an inner diameter not more than about one
`
`French smaller than the inner diameter of the standard guide catheter, a cross-
`
`sectional outer diameter, and a length that is shorter than the predefined length of
`
`the continuous lumen of the standard guide catheter, id., 25:8-18; 26:5-16; 30:1-2,
`
`5-6; 31:6; 32:2-20; 50; 52; 59 at Figure 14.
`
` The application discloses then inserting a substantially rigid portion of
`
`the coaxial guide catheter into the continuous lumen of the standard guide catheter,
`
`id., 30:1-2; 33:1-3; 39:19-40:10; 50, where the substantially rigid portion is
`
`proximal of, operably connected to, and more rigid along a longitudinal axis than
`
`the flexible tip portion, defines a rail structure without a lumen, and has a maximal
`
`cross-sectional dimension at a proximal portion that is smaller than the cross-
`
`sectional outer diameter of the flexible tip portion and a length that, when
`
`combined with the length of the flexible distal tip portion, defines a total length of
`
`the coaxial guide catheter along the longitudinal axis that is longer than the length
`
`15
`
`
`
`of the continuous lumen of the standard guide catheter, wherein a distal portion of
`
`the substantially rigid portion includes a side opening that is sized and configured
`
`to receive the treatment catheter that includes a stent, id., 24:14-16; 25:3-7; 26:3-6;
`
`26:17-27:5; 28:3-19; 29:15-18; 30:1-2, 7-8, 13-15; 31:4-8; 32:4-5; 34:4-19; 37:7-
`
`13; 39:19-40:18; 50; 53; 55; 59.
`
` The priority application also discloses then advancing a distal portion
`
`of the flexible tip portion distally beyond the distal end of the standard guide
`
`catheter and into the branch artery such that the distal portion of the flexible tip
`
`portion extends into the branch artery and such that at least a portion of the
`
`proximal portion of the substantially rigid portion extends proximally through the
`
`hemostatic valve, and inserting the treatment catheter that includes a stent into and
`
`through the continuous lumen of the standard guide catheter alongside the rail
`
`structure of the substantially rigid portion and advancing the treatment catheter that
`
`includes a stent through the side opening and beyond the single lumen of the
`
`flexible tip portion into contact with or past a lesion in the branch artery, id.,
`
`24:14-16; 25:3-7; 28:7-13; 29:16-18; 30:16-20; 36:1-10; 39:19-40:10; 56; 57.
`
`B.
`
`
`
`Substitute Claim 16
`I understand that substitute claim 16 reads as follows:
`
`Substitute claim 16 (replaces claim 7). The method as claimed in claim [[1]]
`
`15, such that when further comprising extending a distal portion of the tubular
`
`16
`
`
`
`structure is extended beyond the distal end of the standard guide catheter while a
`
`proximal portion of the tubular structure remains within the lumen of the standard
`
`guide catheter, such that the coaxial guide catheter assists in resisting axial and
`
`shear forces exerted by the treatment catheter that includes a stent when
`
`interventional cardiology device passed through and beyond the coaxial lumen that
`
`would otherwise tend to dislodge the standard guide catheter from the branch
`
`artery, wherein the standard guide catheter is a standard 6 French guide catheter,
`
`and wherein the inner diameter of the tubular structure is at least 0.056 inches.
`
`
`
`It is my opinion that all elements of substitute claim 16 are supported
`
`by the application. Specifically, the priority application discloses that, when a
`
`distal portion of the tubular structure is extended beyond the distal end of the
`
`standard guide catheter while a proximal portion of the tubular structure remains
`
`within the lumen of the standard guide catheter, the coaxial guide catheter assists
`
`in resisting axial and shear forces exerted by the treatment catheter that includes a
`
`stent when passed through and beyond the coaxial lumen that would otherwise
`
`tend to dislodge the standard guide catheter from the branch artery. Ex-1003, 28:1-
`
`29:12; 30:13-20; 15:4-36:10; 40:11-18; 55-57.
`
` The priority application further discloses that the guide catheter can be
`
`a standard 6 French guide catheter and that the inner diameter of the tubular
`
`structure is at least 0.056 inches. Id., 25:8-18.
`
`17
`
`
`
`C.
`
`
`
`Substitute Claim 17
`I understand that substitute claim 17 reads as follows:
`
`Substitute claim 17 (replaces claim 8). The method of claim 16[[7]], further
`
`comprising extending the interventional cardiology device wherein advancing the
`
`treatment catheter that includes a stent through the side opening includes
`
`advancing the treatment catheter that includes a stent past two inclined sidewalls
`
`spaced apart by a non-inclined concave track, and extending the treatment catheter
`
`that includes a stent past a radiopaque marker proximate a distal tip of the coaxial
`
`guide catheter.
`
`
`
`It is my opinion that all elements of substitute claim 17 are disclosed
`
`in the application. Specifically, the application discloses extending the treatment
`
`catheter that includes a stent through a side opening that includes two inclined
`
`sidewalls spaced apart by a non-inclined concave track. Ex-1003, 26:18-27:5;
`
`30:7-8, 11-12; 31:4-8; 33:1-14; 34:15-19; 37:7-13; 53; 54; 59.
`
`
`
`It further discloses extending the treatment catheter that includes a
`
`stent past a radiopaque marker proximate a distal tip of the coaxial guide catheter.
`
`Id., 25:19-26:2; 26:7-11; 32:7-13.
`
`VIII. NEXUS
`I have been asked to provide my opinions as to whether there is a
`
`
`nexus between the invention claimed in substitute claims 15 and 17 and the
`
`18
`
`
`
`objective evidence of nonobviousness. Specifically, I have been asked whether
`
`claim 15 or 17 of the ’413 patent literally reads on the GuideLiner products.
`
` Based on my review of the claims, the information provided to me in
`
`connection with these IPRs, my familiarity with the GuideLiner products, and my
`
`manual inspection of the three versions of the GuideLiner products, it is my
`
`opinion that claim 15 literally covers all three versions of GuideLiner and that
`
`claim 17 literally covers GuideLiner V3, as explained in Appendix B and below.
`
`GuideLiner is not merely a component, part, or feature of the claimed invention; it
`
`embodies the full claimed invention.
`
` Based on my understanding from the declarations of Dr. Graham, Dr.
`
`Azzalini, and Dr. Thompson and my conversation with Dr. Graham, as well as my
`
`own understanding of the GuideLiner product and its use, the GuideLiner provided
`
`very important clinical benefits: GuideLiner’s use allowed physicians, for the first
`
`time, to take advantage of a specialty catheter that provided the necessary backup
`
`support as well as “rapid exchange” functionality and real-estate maximizing
`
`design that allowed physicians to receive and deliver the full array of
`
`interventional cardiology devices (including stents) deep into the vasculature. Ex-
`
`2145, ¶¶76-77, 85-91, 223-24 (Declaration of Dr. Graham); Ex-2151 (Declaration
`
`of Dr. Azzalini); Ex-2215, ¶¶21-25 (Declaration of Dr. Thompson).
`
`19
`
`
`
` The combination of steps recited in independent substitute claim 15
`
`provided these benefits. The “rapid exchange” functionality is reflected in claim
`
`15’s requirement of inserting a treatment catheter that includes a stent through the
`
`guide catheter, alongside the coaxial guide catheter’s substantially rigid segment,
`
`while maintaining the coaxial guide catheter’s distal portion beyond the end of the
`
`guide catheter. Claim 15 recites the rapid exchange structure, stating, “inserting a
`
`cylindrical flexible tip portion of a coaxial guide catheter” that has “a cross-
`
`sectional outer diameter, and a length that is shorter than the predefined length of
`
`the continuous lumen of the standard guide catheter” into the guide catheter, and
`
`“further inserting a substantially rigid portion of the coaxial guide catheter that is
`
`proximal of, operably connected to” “and having a maximal cross-sectional
`
`dimension at a proximal portion that is smaller than the cross-sectional outer
`
`diameter of the flexible tip portion” into the guide catheter, where “the
`
`substantially rigid portion defin[es] a rail structure without a lumen and ha[s] a
`
`length that, when combined with the length of the flexible distal tip portion,
`
`defines a total length of the coaxial guide catheter along the longitudinal axis that
`
`is longer than the length of the continuous lumen of the standard guide catheter.”
`
` The ability to receive the full array of interventional cardiology
`
`devices (including stents) deep into the vasculature directly results from the
`
`combination of several claimed features, including claim 15’s requirement that
`
`20
`
`
`
`“the flexible tip portion defin[es] a tubular structure . . . with a single lumen that is
`
`coaxial with the lumen of the standard guide catheter [and has] an inner diameter
`
`not more than about one French smaller than the inner diameter of the standard
`
`guide catheter,” as well as claim 15’s requirement of inserting a substantially rigid
`
`portion of the coaxial guide catheter “into the continuous lumen of the standard
`
`guide catheter” “wherein a distal portion of the substantially rigid portion includes
`
`a side opening that is sized and configured to receive the treatment catheter that
`
`includes a stent.”
`
` The improved backup support results from the combination of several
`
`claimed features, including at least the use of a flexible tip portion having a
`
`circular cross section with a diameter that fits within the guide catheter and the
`
`claimed step of advancing the distal portion of the flexible tip portion beyond the
`
`distal end of the guide catheter while the remainder is inside the guide catheter.
`
`Specifically, claim 15 requires “inserting a cylindrical flexible tip portion of a
`
`coaxial guide catheter, the flexible tip portion defining a tubular structure having a
`
`circular cross-section . . . into the continuous lumen of the standard guide
`
`catheter,” and “advancing a distal portion of the flexible tip portion distally beyond
`
`the distal end of the standard guide catheter and into the branch artery such that the
`
`distal portion of the flexible tip portion extends into the branch artery and such that
`
`at least a portion of the proximal portion of the substantially rigid portion extends
`
`21
`
`
`
`proximally through the hemostatic valve.” This method results in improved
`
`backup support (over the guide catheter alone) due to the combination of the
`
`tubular portion being deep seated in the vasculature (beyond the end of the guide
`
`catheter), the interaction between the portion of the tubular portion still inside the
`
`guide catheter and the guide catheter walls, the configuration of the tubular
`
`structure and its size relative to the guide catheter (including the tubular portion
`
`having “a single lumen that is coaxial with the lumen of the standard guide catheter
`
`[and] an inner diameter not more than about one French smaller than the inner
`
`diameter of the standard guide catheter”), and the substantially rigid portion
`
`allowing the cardiologist to control the tubular portion.
`
`
`
`In addition to the combination of steps recited in claim 15, claim 17
`
`further recites “advancing the treatment catheter that includes a stent through the
`
`side opening includes advancing the treatment catheter that